Collaboration - August 26, 2020
Karolinska Institutet, St. Erik Eye Hospital and Novo Nordisk collaborate
Karolinska Institutet and St. Erik Eye Hospital have entered into a collaboration with Novo Nordisk A/S to develop a new treatment for age-related macular degeneration. Novo Nordisk will provide support and SEK 48 million in funding to enable a phase 1 clinical trial where new retinal cells generated from embryonic stem cells will be transplanted […]
Pharma Business - August 18, 2020
Novo Nordisk invests 850 million DKK in production facilities
Novo Nordisk has announced plans to invest DKK 850 million in expanding its production facilities in Kalundborg, Denmark. This new investment brings Novo Nordisk’s total investments in site Kalundborg to more than DKK 2 billion in 2020. Novo Nordisk currently manufactures a range of diabetes care products in Kalundborg, and the new investment will be […]
New Market - July 28, 2020
Rybelsus approved in Japan for the treatment of type 2 diabetes
Novo Nordisk has announced that the Japanese Ministry of Health, Labour and Welfare has approved Rybelsus (oral semaglutide), the first and only oral glucagon-like peptide-1 receptor agonist (GLP-1 RA) in a tablet, for the treatment of adults with type 2 diabetes. The approval of Rybelsus in Japan is based on results from the PIONEER clinical […]
Acquisition - June 18, 2020
Novo Nordisk to acquire Corvidia Therapeutics
Novo Nordisk has entered into a definitive agreement to acquire Corvidia Therapeutics Inc., a privately held, clinical stage company focused on the research and development of transformative therapies for cardio-renal diseases. Corvidia Therapeutics’ lead candidate, ziltivekimab, a fully human monoclonal antibody directed against Interleukin-6 (IL-6), is being developed to reduce the risk of major adverse […]
Clinical Trials - June 16, 2020
Novo Nordisk announces Phase 2 results
Novo Nordisk announced results from a phase 2 clinical trial of investigational insulin icodec, a once-weekly basal insulin analogue. In the trial, adults with type 2 diabetes randomised to once-weekly insulin icodec achieved similar blood sugar control and a similar safety profile compared with adults with type 2 diabetes randomised to once-daily insulin glargine U100. […]
Pharma Business - May 28, 2020
Novo Nordisk launches new strategy to defeat diabetes
Novo Nordisk has announced the launch of a new social responsibility strategy, Defeat Diabetes. The strategy strengthens Novo Nordisk’s commitment and introduces new long-term ambitions to provide access to affordable diabetes care to vulnerable patients in every country and to ensure that no child should die from type 1 diabetes, it states. “Our purpose to […]
